No outcome disparities in patients with diffuse large B-cell lymphoma and a low socioeconomic status |
| |
| Affiliation: | 1. Department of Internal Medicine, University Medical Center Groningen, PO Box 30 001, 9700 RB Groningen, The Netherlands;2. Department of Hematology, Medical Center Leeuwarden, PO Box 888, 8901 BR Leeuwarden, The Netherlands;3. Department of Clinical Pharmacy, Medical Center Leeuwarden, PO Box 888, 8901 BR Leeuwarden, The Netherlands;4. Department of Pathology, Pathology Friesland, PO Box 3305, 901 DH Leeuwarden, The Netherlands;5. Department of Clinical chemistry, Medical Center Leeuwarden KCL, PO Box 888 8901 BR Leeuwarden, The Netherlands;6. Department of Internal Medicine, Nij Smellinghe, PO Box 20200 9200 DA Drachten, The Netherlands;7. Department of Internal Medicine, Antonius Hospital, PO Box 20 000, 8600 BA Sneek, The Netherlands;8. Department of Internal Medicine, Tjongerschans, PO Box 10500, 8440 MA Heerenveen, The Netherlands;9. Department of Epidemiology, University Medical Center Groningen, University of Groningen, PO Box 30 001, 9700 RB Groningen, The Netherlands;10. Department of Epidemiology, University Medical Center Groningen, University of Groningen, PO Box 30 001, 9700 RB Groningen, The Netherlands;11. Department of Hematology, University Medical Center Groningen, University of Groningen, PO Box 30 001, 9700 RB Groningen, The Netherlands;12. Department of Epidemiology, University Medical Center Groningen, University of Groningen, PO Box 30 001, 9700 RB Groningen, The Netherlands |
| |
| Abstract: | IntroductionIn patients with diffuse large B-cell lymphoma (DLBCL) socioeconomic status (SES) is associated with outcome in several population-based studies. The aim of this study was to further investigate the existence of disparities in treatment and survival.MethodsA population-based cohort study was performed including 343 consecutive patients with DLBCL, diagnosed between 2005 and 2012, in the North-west of the Netherlands. SES was based on the socioeconomic position within the Netherlands by use of postal code and categorized as low, intermediate or high. With multivariable logistic regression and Cox proportional hazard models the association between SES and respectively treatment and overall survival (OS) was evaluated.ResultsTwo-third of patients was positioned in low SES. Irrespective of SES an equal proportion of patients received standard immunochemotherapy. SES was not a significant risk indicator for OS (intermediate versus low SES: hazard ratio (HR) 1.31 (95%CI 0.78–2.18); high versus low SES: HR 0.83 (95%CI 0.48–1.46)). The mortality risk remained significantly increased with higher age, advanced performance status, elevated LDH and presence of comorbidity.ConclusionWithin the setting of free access to health care, in this cohort of patients with DLBCL no disparities in treatment and survival were seen in those with lower SES. |
| |
| Keywords: | DLBCL Socioeconomic status Population-based |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
